Figure 2From: An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration Amikacin serum concentration-time data for Patient P2. The arrow indicates the point at which CVVHDF was ceased. The shaded areas indicate the target therapeutic peak and trough ranges.Back to article page